5f688f1aa718f8b9dfc1d7fc3ef47e90_unair

2
Dokumen Artikel Penelitian ini milik penulis/peneliti yang diserahkan sebagian (judul dan Abstrak) hak ciptanya kepada Universitas Airlangga untuk digunakan referensi dalam penulisan artikel ilmiah. Tim Peneliti : Prof.Dr.Indropo Agusni, dr.,Sp.KK (K) Kadar antibody terhadap PGL-1 pada penderita kusta yang mendapat pengobatan kombinasi MDT-WHO Abstrak : Abstract (English) : ANTI PGL-1 ANTIBODY LEVEL IN LEPROSY PATIENTS UNDER WHO-MDT TREATMENT A retrospective study was conducted to 111 leprosy patients of Dr.Soetomo General Hospital who were treated with Multi-drugs therapy (MDT) during the 1994-1995 period, to observe the correlation of the anti Phenolic Glycolipid-1 (PGL-1) level with the clinical and bacteriological status, as well as the length of MDT treatment. The diagnosis and classification of leprosy was based on the WHO-MDT (1988). A modification of Ridley and Jopling classification was also established, without histopathological study and Lepromin test. The MDT regimens still followed the old system, 6 months therapy for Paucibacillary (PB) and 24 months for Multibacillary (MB) leprosy. The serologic examination was performed in the first trimester of 1995, to measure the level of IgM anti PGL-1 antibody using the ELISA method. The average level of IgM anti PGL-1 was relatively low in PB leprosy (0.0259 OD), if compared with MB leprosy (0.0837 OD). Following the 5 subtypes of leprosy, the average level of anti PGL-1 were 0,0141 OD in TT, 0,0270 OD (BT), 0,0423 OD (BB), 0,1031 OD (BL) and 0,1476 OD in LL subtypes. The level of IgM anti PGL-1 increases following the number of Bacteriological Index, but not to the Morphological Index. Decreasing level of the anti PGL-1 antibody was observed in progress of MDT, but some MB patients still have a high antibody titer although they were already treated more than 12 months. Implications of monitoring antibody level and its application in MDT Programme are discussed. Key words : leprosy - MDT treatment - serology - anti PGL-1 antibody Abstract (Indonesian) Page 1

Upload: widya-syah-fitri

Post on 30-Sep-2015

3 views

Category:

Documents


0 download

DESCRIPTION

meningioma

TRANSCRIPT

  • Dokumen Artikel Penelitian ini milik penulis/peneliti yang diserahkan sebagian (judul dan Abstrak) hak ciptanya kepada Universitas Airlangga untukdigunakan referensi dalam penulisan artikel ilmiah.

    Tim Peneliti : Prof.Dr.Indropo Agusni, dr.,Sp.KK (K)

    Kadar antibody terhadap PGL-1 pada penderita kusta yang mendapatpengobatan kombinasi MDT-WHO

    Abstrak :

    Abstract (English)

    :

    ANTI PGL-1 ANTIBODY LEVEL IN LEPROSY PATIENTSUNDER WHO-MDT TREATMENT

    A retrospective study was conducted to 111 leprosy patients of Dr.Soetomo General Hospital who weretreated with Multi-drugs therapy (MDT) during the 1994-1995 period, to observe the correlation of the antiPhenolic Glycolipid-1 (PGL-1) level with the clinical and bacteriological status, as well as the length of MDT treatment. The diagnosis and classification of leprosy was based on the WHO-MDT (1988). Amodification of Ridley and Jopling classification was also established, without histopathological study andLepromin test. The MDT regimens still followed the old system, 6 months therapy for Paucibacillary (PB)and 24 months for Multibacillary (MB) leprosy. The serologic examination was performed in the firsttrimester of 1995, to measure the level of IgM anti PGL-1 antibody using the ELISA method. The averagelevel of IgM anti PGL-1 was relatively low in PB leprosy (0.0259 OD), if compared with MB leprosy(0.0837 OD). Following the 5 subtypes of leprosy, the average level of anti PGL-1 were 0,0141 OD in TT,0,0270 OD (BT), 0,0423 OD (BB), 0,1031 OD (BL) and 0,1476 OD in LL subtypes. The level of IgM anti PGL-1 increases following the number of BacteriologicalIndex, but not to the Morphological Index. Decreasing level of the anti PGL-1 antibody was observed in progress of MDT, but some MB patients still have a high antibody titer although they were already treated more than12 months. Implications of monitoring antibody level and its application in MDT Programme are discussed.

    Key words

    :

    leprosy - MDT treatment - serology - anti PGL-1 antibody

    Abstract (Indonesian)

    Page 1

  • Dokumen Artikel Penelitian ini milik penulis/peneliti yang diserahkan sebagian (judul dan Abstrak) hak ciptanya kepada Universitas Airlangga untukdigunakan referensi dalam penulisan artikel ilmiah.

    Tim Peneliti : Prof.Dr.Indropo Agusni, dr.,Sp.KK (K)

    :

    KADAR

    ANTIBODI

    TERHADAP

    PHENOLIC GLYCOLIPID-1 ( PGL-1 ) PADA PENDERITA KUSTA YANG MENDAPAT PENGOBATAN KOMBINASI MDT-WHOSuatu penelitian retrospektif di RSUD Dr Soetomo Surabaya

    Telah dilakukan suatu penelitian retrospektif pada 111 penderita kusta yang menjalani pengobatankombinasi Multi-drugs Therapy (MDT) di RSUD Dr Soetomo Surabaya pada periode 1994- 1995 dan telahmenjalani pemeriksaan serologis kusta. Penelitian ini bertujuan untuk mengetahui hubungan antara kadarantibodi terhadap Phenolic Glycolipid-1 (PGL-1), suatu antigen spesifik untuk Mycobacterium leprae,dengan klasifikasi klinis, indeks bakteriologis, indeks morfologis dan lamanya pengobatan MDT. Diagnosakusta ditegakkan dengan kriteria WHO, 1988 , demikian pula klasifikasinya namun ditambah denganmodifikasi klasifikasi Ridley & Jopling. Pengobatan MDT yang digunakan masih dengan cara lama,yaitu 6 bulan untuk kusta PB dan 24 bulan untuk MB.Pemeriksaan serologi dilakukan pada trimester awal1995 memakai metode ELISA untuk mengukur kadar antibodi IgM anti PGL-1 dari darah penderita.Didapatkan kadar antibodi IgM anti PGL-1 yang rendah pada tipe PB (rerata 0.0259 OD) dibandingkandengan tipe MB (0,0837 OD). Angka rerata dari antibodi tersebut pada ke 5 subtipe kusta adalah 0,0141OD pada tipe TT, 0,0270 OD (BT), 0,0423 OD (BB), 0,1031 OD (BL) dan 0,1476 OD pada tipe LL.Terlihat kenaikan kadar anti PGL-1 sesuai dengan meningkatnya angka Indeks Bakteriologis, namuntampaknya Indeks Morfologis tidak berpengaruh pada kadar IgM anti PGL-1. Kadar antibodi anti PGL-1ini secara lambat menurun dengan semakin lamanya MDT yang diberikan, namun pada tipe MB kadarnya masih cukuptinggi walaupun MDT telah diberikan lebih dari 12 bulan. Dibahas mengenai berbagai implikasipemantauan kadar antibodi dalam program pengobatan MDT.

    Kata kunci : kusta - pengobatan MDT -

    serologi - antibodi anti PGL-1

    Keyword :

    leprosy, MDT treatment, serology, anti PGL-1 antibody.

    Page 2